Información del artículo
Lupus nephritis is a relevant source of morbidity and mortality in patients with systemic lupus erythematosus. The standard therapy of remission induction in severe lupus nephritis is based on the use of monthly intravenous cyclophosphamide. Recent data have established that the maintenance of remission in lupus nephritis can be achieved with azathioprine or mycophenolate mofetil, with less adverse effects than quarterly intravenous cyclophosphamide. In recent years, a number of controlled randomized clinical trials have been published, opening new therapeutic options in the induction of remission in lupus nephritis, such as less aggressive regimens of intravenous cyclophosphamide or mycophenolate mofetil. Further studies are needed for establishing the optimal therapy of lupus nephritis patients.
Key words:
Lupus nephritis
Mycophenolate mofetil
Cyclophosphamide
Systemic lupus erythematosus
La nefritis lúpica es una causa importante de morbilidad y mortalidad en los pacientes con lupus eritematoso sistémico. El tratamiento convencional de inducción de remisión en la nefritis lúpica grave se basa en la utilización de ciclofosfamida intravenosa mensual. Datos recientes han puesto de manifiesto que el mantenimiento de remisión de la nefritis lúpica se consigue con un menor número de efectos secundarios utilizando azatioprina o micofenolato, frente a la administración trimestral de ciclofosfamida intravenosa. En los últimos años se han publicado ensayos clínicos controlados y aleatorizados que plantean nuevas modalidades terapéuticas en la inducción de remisión en la nefritis lúpica, como son la utilización de pautas menos agresivas de ciclofosfamida intravenosa o el uso de micofenolato mofetilo. Se necesitan más estudios para establecer el tratamiento óptimo de los pacientes con nefritis lúpica grave.
Palabras clave:
Nefritis lúpica
Micofenolato mofetilo
Ciclofosfamida
Lupus eritematoso sistémico
El Texto completo está disponible en PDF
References
[1.]
D.L. Jacobson, S.J. Gange, N.R. Rose, N.M. Graham.
Epidemiology and estimated population burden of selected autoinmune diseases in the United States.
Clin Immunol Immunopathol, 84 (1997), pp. 223-243
[2.]
A.E. Johnson, C. Gordon, R.G. Palmer, P.A. Bacon.
The prevalence and incidence of systemic lupus erythematosus in Birmingham.
England. Relationship to ethnicity and country of birth. Arthritis Rheum, 38 (1995), pp. 551-558
[3.]
R. Cervera, M.A. Khamashta, J. Font, G.D. Sebastiani, A. Gil, P. Lavilla, et al.
Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1000 patients.
Medicine (Baltimore), 72 (1993), pp. 113-124
[4.]
R. Cervera, M.A. Khamashta, J. Font, G.D. Sebastiani, A. Gil, P. Lavilla, et al.
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients.
Medicine (Baltimore), 82 (2003), pp. 299-308
[5.]
J. Golbus, W.J. McCune.
Lupus nephritis, Classification, prognosis, immunopathogenesis and treatment.
Rheum Dis Clin North Am, 20 (1994), pp. 213-242
[6.]
A.J. Howie, N. Turhan, D. Adu.
Powerful morphometric indicator of prognosis in lupus nephritis.
QMJ, 96 (2003), pp. 411-420
[7.]
C.C. Mok, K.Y. Ying, S. Tang, C.Y. Leung, K.W. Lee, W.L. Ng, et al.
Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.
Arthritis Rheum., 50 (2004), pp. 2559-2568
[8.]
J. Churg, L.H. Sobin.
Renal Disease:Classification and Atlas of Glomerular Disease.
Igaku-Shoin, (1982),
[9.]
J.J. Weening, V.D. D’Agati, M.M. Schwartz, S.V. Seshan, C.E. Alpers, G.B. Appel, et al.
The classification of glomerulonephritis in systemic lupus erythematosus revisited.
Kidney International, 65 (2004), pp. 521-530
[10.]
A.D. Steinberg, S.C. Steinberg.
Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only.
Arthritis Rheum, 34 (1991), pp. 945-950
[11.]
H.A. Austin 3rd, J.H. Klippel, J.E. Balow, N.G. le Riche, A.D. Steinberg, P.H. Plotz, et al.
Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.
N Engl J Med, 314 (1986), pp. 614-619
[12.]
D.T. Boumpas, H.A. Austin 3rd, E.M. Vaughan, J.H. Klippel, A.D. Steinberg, C.H. Yarboro, et al.
Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.
Lancet, 340 (1992), pp. 741-745
[13.]
G.G. Illei, H.A. Austin, M. Crane, L. Collins, M.F. Gourley, C.H. Yarboro, et al.
Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxiciy in patients with lupus nephritis.
Ann Intern Med, 135 (2001), pp. 248-257
[15.]
C.C. Mok, C.T. Ho, Y.P. Siu, K.W. Chan, T.H. Kwan, C.S. Lau, et al.
Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens.
Am J Kidney Dis, 38 (2001), pp. 256-264
[16.]
C.S. Yee, C. Gordon, C. Dostal, P. Petera, J. Dadoniene, B. Griffiths, et al.
EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
Ann Rheum Dis, 63 (2004), pp. 525-529
[17.]
F.A. Houssiau, C. Vasconcelos, D. D’Cruz, G.D. Sebastiani, E. Garrido, M.G. Danieli, et al.
Immunosuppressive therapy in lupus nephritis. The Euro-Lupus Nephritis Trial, a Randomized Trial of Low-Dose Versus High-Dose Intravenous Cyclophosphamide.
Arthritis Rheum, 46 (2002), pp. 2121-2131
[18.]
F.A. Houssiau, C. Vasconcelos, D. D’Cruz, G.D. Sebastiani, E. Garrido, M.G. Danieli, et al.
Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis.
Arthritis Rheum, 50 (2004), pp. 3934-3940
[19.]
G.G. Illei, K. Takada, D. Parkin, H.A. Austin, M. Crane, C.H. Yarboro, et al.
Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies.
Arthritis Rheum, 46 (2002), pp. 995-1002
[20.]
J.P.A. Ioannidis, K.A. Boki, M.E. Katsorida, A.A. Drosos, F.N. Skopouli, J.N. Boletis, et al.
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide.
Kidney Int, 57 (2000), pp. 258-264
[23.]
R.S. Flanc, M.A. Roberts, G.F. Strippoli, S.J. Chadban, P.G. Kerr, R.C. Atkins.
Treatment of diffuse proliferative lupus nephritis: a metaanalysis of randomized controlled trials.
Am J Kidney Dis, 43 (2004), pp. 197-208
[24.]
A.C. Allison.
Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation.
Transplant Proc, 26 (1994), pp. 3205-3210
[25.]
M.A. Dooley, F.G. Cosio, P.H. Nachman, M.E. Fankelhaim, S.L. Hogan, R.J. Falk, et al.
Mycophenolate mofetil therapy in lupus nephritis: clinical observations.
J Am Soc Nephrol, 10 (1999), pp. 833-839
[26.]
M. Gaubitz, A. Schorat, H. Schotte, P. Kern, W. Domschke.
Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial.
Lupus, 8 (1999), pp. 731-736
[27.]
E.J. Kingdon, A.G. McLean, E. Psimenous, A. Davenport, S.H. Powis, P. Sweny, et al.
The safety and efficacy of MMF in lupus nephritis: a pilot study.
Lupus, 10 (2001), pp. 606-611
[28.]
M.Y. Karim, P. Alba, M.J. Cuadrado, I.C. Abbs, D.P. D’Cruz, M.A. Khamashta, et al.
Mycophenolate mofetil for systemic lupus erythematosus refactory to other immunosuppressive agents.
Rheumatology (Oxford), 41 (2002), pp. 876-882
[29.]
P.P. Kapitsinou, J.N. Boletis, F.N. Skopouli, K.A. Boki, H.M. Moutsopoulos.
Lupus nephritis: treatment with mycophenolate mofetil.
Rheumatology (Oxford), 43 (2004), pp. 377-380
[30.]
C.N. Pisoni, F.J. Sanchez, Y. Karim, M.J. Cuadrado, D.P. D’Cruz, I.C. Abbs, et al.
Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients.
J Rheumatol, 32 (2005), pp. 1047-1052
[31.]
M.Y. Karim, C.N. Pisoni, L. Ferro, M.F. Tungekar, I.C. Abbs, D.P. D’Cruz, et al.
Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy.
Rheumatology (Oxford), 44 (2005), pp. 1317-1321
[32.]
T.M. Chan, F.K. Li, C.S. Tang, R.W. Wong, G.X. Fang, Y.L. Ji, et al.
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis.
Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med, 343 (2000), pp. 1156-1162
[33.]
T.M. Chan, K.C. Tse, C.S. Tang, M.Y. Mok, F.K. Li.
Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.
J Am Soc Nephrol, 16 (2005), pp. 1076-1084
[34.]
W. Hu, Z. Liu, H. Chen, Z. Tang, Q. Wang, K. Shen, et al.
Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
Chin Med J (Engl), 115 (2002), pp. 705-709
[35.]
L.M. Ong, L.S. Hooi, T.O. Lim, B.L. Goh, G. Ahmad, R. Ghazalli, et al.
Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
Nephrology, 10 (2005), pp. 504-510
[36.]
E.M. Ginzler, M.A. Dooley, C. Aranow, M.Y. Kim, J. Buyon, J.T. Merrill, M. Petri, et al.
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
N Engl J Med, 353 (2005), pp. 2219-2228
[37.]
R.A. Moore, S. Derry.
Systematic review and meta-analysis of randomised trails and cohort studies of mycophenolate mofetil in lupus nephritis.
Arthritis Res Ther, 8 (2006), pp. R182
[38.]
A. Sinclair, G. Appel, M.A. Dooley, E. Ginzler, D. Isenberg, D. Jayne, et al.
Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).
Lupus, 16 (2007), pp. 972-980
[39.]
R. Cade, G. Spooner, E. Schlein, M. Pickering, A. DeQuesada, A. Holcomb, et al.
Comparison of azathioprine, prednisone and heparin, alone or combined in treating lupus nephritis.
Nephron, 10 (1973), pp. 37-56
[40.]
J.V. Donadio, K.E. Holley, R.D. Wagoner, R.H. Ferguson, F.C. McDuffie.
Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine.
Arthritis Rheum, 17 (1974), pp. 573-581
[41.]
B.H. Hahn, O.S. Kantor, C.K. Osterland.
Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus.
Ann Intern Med, 83 (1975), pp. 597-605
[42.]
C. Grootscholten, G. Ligtenberg, E.C. Hagen, A.W. van den Wall Bake, J.W. de Glas-Vos, M. Bijl, et al.
Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
Kidney Int, 70 (2006), pp. 732-742
[43.]
C. Grootscholten, I.M. Bajema, S. Florquin, E.J. Steenbergen, C.J. Peutz-Kootstra, R. Goldschmeding, et al.
Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
Arthritis Rheum, 56 (2007), pp. 924-937
[44.]
E. Ciruelo, J. de la Cruz, I. López, J.J. Gómez-Reino.
Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide.
Arthritis Rheum, 39 (1996), pp. 2028-2034
[45.]
C.C. Mok, R.W.S. Wong, K.N. Lai.
Treatment of severe proliferative lupus nephritis: the current state.
Ann Rheum Dis, 62 (2003), pp. 799-804
[47.]
T.M. Chan, K.C. Tse, C.S.O. Tang, K.N. Lai, F.K. Li.
Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine.
Lupus, 14 (2005), pp. 265-272
[48.]
G. Contreras, V. Pardo, B. Leclercq, O. Lenz, E. Tozman, P. O’Nan, et al.
Sequential therapies for proliferative lupus nephritis.
N Engl J Med, 350 (2004), pp. 971-980
[49.]
G. Contreras, E. Tozman, N. Nahar, D. Metz.
Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Lupus, 14 (2005), pp. s33-s38
[50.]
C. Dostál, V. Tesar, I. Rychlík, J. Zabka, J. Vencovsk?, J. Bartûnkova, et al.
Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study.
Lupus, 7 (1998), pp. 29-36
[51.]
D. Caccavo, B. Lagana, A.P. Mitterhofer, G.M. Ferri, A. Afeltra, A. Amoroso, et al.
Long-term treatment of systemic lupus erythematosus with Cyclosporin A.
Arthritis Rheum, 40 (1997), pp. 27-35
[52.]
D. Hallegua, D.J. Wallace, Metzger Al, R.Z. Rinaldi, J.R. Klinenberg.
Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature.
Lupus, 9 (2000), pp. 241-251
[53.]
L.S. Tam, E.K. Li, C.B. Leung, K.C. Wong, F.M.M. Lai, A. Wang, et al.
Longterm treatment of lupus nephritis with cyclosporin A.
Q J Med, 91 (1998), pp. 573-580
[54.]
G. Moroni, A. Doria, M. Mosca, O.D. Alberighi, G. Ferraccioli, S. Todesco, et al.
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
Clin J Am Soc Nephrol, 1 (2006), pp. 925-932
[55.]
C.C. Mok.
Therapeutic options for resistant lupus nephritis.
Semin Arthritis Rheum, 36 (2006), pp. 71-81
[56.]
C.C. Mok, K.H. Tong, C.H. To, Y.P. Siu, T.C. Au.
Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: An open-labeled pilot study.
Kidney Int, 68 (2005), pp. 813-817
[57.]
K.C. Tse, M.F. Lam, S.C.W. Tang, C.S.O. Tang, T.M. Chan.
A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade.
Lupus, 16 (2007), pp. 46-51
[58.]
I. Buhaescu, A. Covic, G. Deray.
Treament of proliferative lupus nephritis – A critical approach.
Semin Arthritis Rheum, 36 (2007), pp. 224-237
[59.]
C.F. Remer, M.H. Weisman, D.J. Wallace.
Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus, 10 (2001), pp. 480-483
[60.]
L.S. Tam, E.K. Li, C.K. Wong, C.W. Lam, C.C. Szeto.
Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.
Lupus, 13 (2004), pp. 601-604
[61.]
T.G. Cui, F.F. Hou, Z.H. Ni, X.M. Chen, F.S. Zhang, T.Y. Zhu, et al.
Treatment of proliferative lupus nephritis with leflunomide and steroid: a prospective multicenter controlled clinical trial.
Zhonghua Nei Ke Za Zhi, 44 (2005), pp. 672-676
[62.]
L.S. Tam, E.K. Li, C.K. Wong, C.W. Lam, W.C. Li, C.C. Szeto.
Satety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open trial.
Ann Rheum Dis, 65 (2006), pp. 417-418
[63.]
E.M. Ginzler, O. Dvorkina.
Newer therapeutic approaches for systemic lupus erythematosus.
Rheum Dis Clin N Am, 31 (2005), pp. 315-328
[64.]
R. Furie.
Abetimus sodium (Riquent) for the prevention of nephritis flares in patients with systemic lupus erythematosus.
Rheum Dis Clin N Am, 32 (2006), pp. 149-156
[65.]
D. Alarcón-Segovia, J.A. Tumlin, R.A. Furie, J.D. McKay, M.H. Cardiel, V. Strand, et al.
LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus.
Arthritis Rheum, 48 (2003), pp. 442-454
[66.]
M.H. Cardiel.
Abetimus sodium: a new therapy for delaying the time to, and reducing the incidence of, renal flare and/or major systemic lupus erythematosus flares in patients with systemic lupus erythematosus who have a history of renal disease.
Expert Opin Investig Drugs, 14 (2005), pp. 77-88
[67.]
D.J. Wallace, J.A. Tumlin.
LJP 394 (abetimus sodium Riquent) in the management of systemic lupus erythematosus.
Lupus, 13 (2004), pp. 323-327
[68.]
V. Strand, C. Aranow, M.H. Cardiel, D. Alarcón-Segovia, R. Furie, Y. Sherrer.
et al for the LJP 394 Investigator Consortium. Improvement in health-related quality of life in SLE patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo.
Lupus, 12 (2003), pp. 677-686
[69.]
M. Aringer, W.B. Graninger, G. Steiner, J.S. Smolen.
Safety and efficacy of tumor necrosis factor a blockade in systemic lupus erythematosus: an openlabel study.
Arthritis Rheum, 50 (2004), pp. 3161-3169
[70.]
M.J. Leandro, J.C. Edwards, G. Cambridge, M.R. Ehrenstein, D.A. Isenberg.
An open study of B lymphocyte depletion in systemic lupus erythematosus.
Arthritis Rheum, 46 (2002), pp. 2673-2677
[71.]
M.J. Leandro, G. Cambridge, J.C. Edwards, M.R. Ehrenstein, D.A. Isenberg.
Bcell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.
Rheumatology, 44 (2005), pp. 1542-1545
[72.]
P.P. Sfikakis, J.N. Boletis, S. Lionaki, V. Vigklis, K.G. Fragiadaki, A. Iniotaki, et al.
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand.
Arthritis Rheum, 52 (2005), pp. 501-513
[73.]
M. Vigna-Pérez, B. Hernández-Castro, O. Paredes-Saharopulos, D. Portales- Pérez, L. Baranda, C. Abud-Mendoza, et al.
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.
Arthritis Res Ther, 8 (2006), pp. R83
[74.]
I. Gunnarsson, B. Sundelin, T. Jónsdóttir, S.H. Jacobson, E.W. Henriksson, R.F. van Vollenhoven.
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.
Arthritis Rheum, 56 (2007), pp. 1263-1272
[75.]
W. Stohl, W. Chatham, J. McKay, M.H. Weisman, J.T. Merrill, M. Petri, For the LBSL02/99 Study Group, et al.
Progressive Normalization of Autoantibody. Immunoglobulin, and Complement Levels Over 2. 5 Years of Belimumab (Fully Human Monoclonal Antibody to BLyS) Therapy in Systemic Lupus Erythematosus (SLE) Patients.
Arthritis Rheum, 56 (2007), pp. S210
[76.]
J.T. Merrill, D.J. Wallace, W. Stohl, R. Furie, E. Ginzler, Stern S, For the LBSL02/99 Study Group, et al.
Safety Profile of Belimumab (Fully Human Monoclonal Antibody to BLyS) in patients with systemic lupus erythematosus (SLE) treated during a placebo-controlled trial and in a long-term continuation study.
Arthritis Rheum, 56 (2007), pp. S210
[77.]
M. Petri, R. Furie, E. Ginzler, D.J. Wallace, W. Stohl, V. Strand, For the LBSL02/99 Study Group., et al.
Novel combined response endpoint and systemic lupus erythematosus (SLE) flare Index (SFI) demonstrate belimumab (Fully Human Monoclonal Antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2. 5 years of therapy.
Arthritis Rheum, 56 (2007), pp. S527
[78.]
V. Strand, B. Crawford, M. Petri, R. Ramsey-Goldman, M. Weisman, Lim S, For the LBSL02 Study Group, et al.
Patients with ative systemic lupus erythematosus (SLE) treated with belimumab improve health-related quality of life (HRQOL) in a randomized controlled trial (RCT).
Arthritis Rheum, 54 (2006), pp. S277
[79.]
E. Toubi, A. Kessel, Y. Shoenfeld.
High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus.
Hum Immunol, 66 (2005), pp. 395-402
[80.]
G. Zandman-Goddard, Y. Levy, Y. Shoenfeld.
Intravenous immunoglobulin therapy and systemic lupus erythematosus.
Clin Rev Allergy Immunol, 29 (2005), pp. 219-228
[81.]
Y. Sherer, Y. Shoenfeld.
Intravenous immnunoglobulin for immunomodulation of systemic lupus erythematosus.
Autoimmunity Reviews, 5 (2006), pp. 153-155
[82.]
J.L. Boletis, J.P. Ioannidis, K.A. Boki, H.M. Moutsopulos.
Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis.
Lancet, 354 (1999), pp. 569-570
[83.]
H. Orbach, M. Tishler, Y. Shoenfeld.
Intravenous immunoglobulin and the kidney - a two-edged sword.
Semin Arthritis Rheum, 34 (2004), pp. 593-601
[84.]
A. Winder, Y. Molad, I. Ostfeld, G. Kenet, J. Pinkhas, Y. Sidi.
treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases.
J Rheumatol, 20 (1993), pp. 495-498
[85.]
Y. Levy, Y. Sherer, J. George, J. Rovensky, J. Lukac, L. Rauova, et al.
Intravenous immunoglobulin treatment of lupus nephritis.
Semin Arthritis Rheum, 29 (2000), pp. 321-327
[86.]
E.J. Lewis, L.G. Hunsicker, S.P. Lan, R.D. Rohde, J.M. Lachin.
A controlled trial of plasmapheresis therapy in severe lupus nephritis.
The Lupus Nephritis Collaborative Study Gro*up. N Engl J Med, 326 (1992), pp. 1373-1379
[87.]
D.J. Wallace, D. Goldfinger, S.H. Pepkowitz, M. Fichman, A.L. Metzger, J.O. Schroeder, et al.
Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis.
J Clin Apher, 13 (1998), pp. 163-166
[88.]
M.G. Danieli, C. Palmieri, A. Salvi, M.C. Refe, A.S. Strusi, G. Danieli.
Synchronized therapy and high-dose cyclophosphamide in proliferative lupus nephritis.
J Clin Apher, 17 (2002), pp. 72-77
[89.]
J. Font, M. Ramos-Casals, R. Cervera, M. García-Carrasco, A. Torras, A. Sisó, et al.
Cardiovascular risk factors and the long-term outcome of lupus nephritis.
Q J Med, 94 (2001), pp. 19-26
[91.]
K.C. Tse, F.K. Li, S. Tang, C.S. Tang, K.N. Lai, T.M. Chan.
Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria.
Lupus, 14 (2005), pp. 947-952
[92.]
W.H. Ettinger, A.P. Goldberg, D. Applebaum-Bowden, W.R. Hazard.
Dyslipoproteinemia in systemic lupus erythematosus.
Am J Med, 83 (1987), pp. 503-508
[93.]
M. Haubitz.
Exploring new territory: the move towards individualised treatment.
Lupus, 16 (2007), pp. 227-231
[94.]
A.S. Wierzbicki.
Lipids cardiovascular disease and atherosclerosis in systemic lupus erythematosus.
Lupus, 9 (2000), pp. 194-201
[95.]
C.C. Mok, K.H. Toug, C.H. To, Y.P. Siu, L.Y. Ho, T.C. Au.
Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study.
Medicine (Baltimore), 86 (2007), pp. 203-209
Copyright © 2008. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
